OncXerna Therapeutics

OncXerna Therapeutics | 1,166 followers on LinkedIn. Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel, targeted treatments | Existing precision medicines target just 10 percent of cancers – those with gene mutations or oncogenic drivers for a small number of genes. Oncologie is ushering in a new era of precision medicine, leveraging the company’s deep understanding of tumor biology at the RNA level to deliver more effective therapies for many more patients. OncXerna Therapeutics applies its understanding of RNA signatures to describe the dominant biology of the patient’s cancer and match it to therapies with mechanisms that modify the dominant biology to dramatically improve patient outcomes.